Anthracycline Cardiotoxicity: Prevention in Cancer Survivors
Summary of the Article: Cardio-Oncology and Preventing Anthracycline-Induced Cardiac Dysfunction
this article discusses the increasing risk of cardiovascular disease in cancer survivors and focuses on preventive strategies for mitigating the cardiac side effects of anthracycline chemotherapy, as presented at the 2025 ESC Cardio-Oncology Annual Conference by Borja Ibáñez, MD, PHD, FESC.
Key Takeaways:
* Increased Cardiovascular Risk: Cancer survivors are at a higher risk of cardiovascular disease, heart failure, and stroke, even self-reliant of conventional risk factors.
* Risk Assessment is Crucial: Clinicians shoudl assess cardiovascular risk before, during, and after cancer treatment, utilizing tools like the HFA-ICOS score.
* HFA-ICOS Score Stratification: A recent study using the HFA-ICOS score categorized patients as:
* Low Risk (54%): Routine oncology follow-up, cardiology referral if toxicity develops.
* Moderate Risk (31%): Closer oncology follow-up, cardiology referral if toxicity develops.
* High Risk (14%): Cardiology referral, discussion of risk/benefit of treatment & cardioprotective strategies.
* Very High Risk (0.9%): Cardiology referral, discussion of risk/benefit of treatment & cardioprotective strategies.Higher incidence of cardiac dysfunction and mortality.
* Preventive Strategies Highlighted:
* SGLT2 Inhibitors (empagliflozin): Preclinical trials show a dose-dependent cardioprotective effect against anthracycline-induced cardiotoxicity, improving left ventricular ejection fraction and cardiac function.
* Remote ischemic Conditioning (RESILIENCE project): A novel intervention being investigated for cardioprotection. Dr. Ibáñez is the coordinator of the RESILIENCE project, aiming to reduce heart failure in cancer survivors.
In essence, the article emphasizes the importance of proactive cardiovascular risk assessment and the potential of emerging therapies like SGLT2 inhibitors and remote ischemic conditioning to protect the hearts of cancer patients undergoing anthracycline chemotherapy.